Supercharged immune cells take on relapsed leukemia in new trial
NCT ID NCT03068819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new approach for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers gave patients a special type of immune cell called cytokine-induced memory-like natural killer (CIML NK) cells, along with donor immune cells, to try to fight the leukemia. The goal was to see if this combination was safe and could help patients achieve remission. The trial enrolled 62 participants and looked at both safety and how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytokine-induced memory-like natural killer (CIML NK) cells
What this could lead to
If this works, it could offer a more effective treatment for patients whose leukemia returns after a stem cell transplant, potentially improving remission rates and survival.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. There are risks of graft-versus-host disease, infections, and other side effects from the cell infusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States